USPTO serial 79386743
RIBOGALSTAR
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Mar 18, 2025
- Examiner
- MASON, JARED MICHAEL
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with RIBOGALSTAR?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Zhi Dong
Zhi Dong HSML, P.C.45 South Seventh Street, Suite 2700No.1 Zhongguancun Street South,Minneapolis, MN 55402Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Medicines for humans for the treatment and diagnosis of cardiovascular diseases, metabolic diseases, liver diseases, genetic disorders and rare ocular, respiratory, gastrointestinal, cerebral diseases; crude drugs being pharmaceutical preparations for the treatment and diagnosis of cardiovascular diseases, metabolic diseases, liver diseases, genetic disorders and rare ocular, respiratory, gastrointestinal, cerebral diseases; pharmaceutical preparations for the treatment and diagnosis of cardiovascular diseases, metabolic diseases, liver diseases, genetic disorders and rare ocular, respiratory, gastrointestinal, cerebral diseases; chemico-pharmaceutical preparations for the treatment and diagnosis of cardiovascular diseases, metabolic diseases, liver diseases, genetic disorders and rare ocular, respiratory, gastrointestinal, cerebral diseases; biological preparations for medical purposes for the treatment and diagnosis of cardiovascular diseases, metabolic diseases, liver diseases, genetic disorders and rare ocular, respiratory, gastrointestinal, cerebral diseases; chemical preparations for pharmaceutical purposes for the treatment and diagnosis of cardiovascular diseases, metabolic diseases, liver diseases, genetic disorders and rare ocular, respiratory, gastrointestinal, cerebral diseases; chemical preparations for medical purposes for the treatment and diagnosis of cardiovascular diseases, metabolic diseases, liver diseases, genetic disorders and rare ocular, respiratory, gastrointestinal, cerebral diseases; drugs for medical purposes, namely, pharmaceutical preparations for the treatment and diagnosis of cardiovascular diseases, metabolic diseases, liver diseases, genetic disorders and rare ocular, respiratory, gastrointestinal, cerebral diseases; diagnostic preparations for medical purposes; potassium salts for medical purposes; sodium salts for medical purposes; pharmaceuticals for the treatment of cancer; anti-cancer preparations; biopharmaceuticals for the treatment of cancer; pharmaceutical preparations for the prevention and treatment of cancer; tumor suppressing agents; pharmaceutical preparations for suppressing tumors; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations for the central nervous system; pharmaceuticals for the treatment of infectious diseases; pharmaceutical preparations for the treatment of hypercholesteremia; pharmaceutical preparations for the treatment of hyperlipidemia; pharmaceutical preparations for treating diabetes; pharmaceutical agents affecting metabolism; anticoagulants; cardiovascular pharmaceuticals; pharmaceutical preparations for ocular or intraocular surgery; dietetic food and beverages adapted for medical use; depuratives for the body; medicines for veterinary purposes, namely, veterinary preparations for the treatment and diagnosis of gastrointestinal diseases, cardiovascular diseases, metabolic diseases, and liver diseases; pesticides; dressings, medical; composite materials for dental purposes; diapers for pets | ACTIVE | — |
| 042 | Technological research in the field of pharmaceutical manufacturing processes and pharmaceutical studies; development of pharmaceutical preparations and medicines; pharmaceutical product evaluation; pharmaceutical research and development services; research in the field of pharmaceuticals; scientific research; chemical research and analysis; development and testing of chemical production methods; biochemical research and analysis; scientific research in the nature of conducting clinical trials for others; medical research; testing of pharmaceuticals; industrial design | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Suzhou Ribo Life Science Co., Ltd.
- Other trademarks owned by Suzhou Ribo Life Science Co., Ltd.
- Other trademarks owned by Suzhou Ribo Life Science Co., Ltd.
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named RIBOGALSTAR
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 18, 2025 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Sep 26, 2025 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Sep 26, 2025 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Jun 20, 2025 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Jun 18, 2025 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jun 3, 2025 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jun 3, 2025 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Mar 18, 2025 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Mar 18, 2025 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jan 28, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 28, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jan 22, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jan 2, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jan 2, 2025 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jan 2, 2025 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jan 2, 2025 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jan 2, 2025 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Dec 30, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 30, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 30, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 4, 2024 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jul 12, 2024 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jul 11, 2024 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jun 21, 2024 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jun 20, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 18, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 9, 2024 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jan 5, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 4, 2024 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |